B. Riley Financial Forecasts Strong Price Appreciation for Compass Pathways (NASDAQ:CMPS) Stock

Compass Pathways (NASDAQ:CMPS) had its price target lifted by research analysts at B. Riley Financial from $17.00 to $22.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. B. Riley Financial’s price target would indicate a potential upside of 61.84% from the stock’s previous close.

A number of other research analysts also recently issued reports on CMPS. Royal Bank Of Canada reissued an “outperform” rating on shares of Compass Pathways in a research report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Pathways in a research report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and set a $70.00 target price on shares of Compass Pathways in a research note on Wednesday, July 8th. Evercore upgraded shares of Compass Pathways from an “in-line” rating to an “outperform” rating and set a $21.00 price target on the stock in a research report on Wednesday, July 8th. Finally, Maxim Group increased their price target on shares of Compass Pathways from $12.00 to $20.00 and gave the stock a “buy” rating in a research note on Friday, May 15th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Compass Pathways has an average rating of “Moderate Buy” and an average target price of $23.71.

Compass Pathways Trading Up 0.1%

NASDAQ CMPS traded up $0.01 on Thursday, hitting $13.59. The company’s stock had a trading volume of 576,765 shares, compared to its average volume of 3,731,034. The firm has a market cap of $1.83 billion, a P/E ratio of -4.32 and a beta of 2.50. Compass Pathways has a 52-week low of $3.97 and a 52-week high of $15.40. The company’s 50-day simple moving average is $12.54 and its 200 day simple moving average is $9.27. The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.15.

Compass Pathways (NASDAQ:CMPS) last posted its earnings results on Wednesday, August 5th. The company reported ($1.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($1.49). Research analysts predict that Compass Pathways will post -1.24 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. EverSource Wealth Advisors LLC increased its stake in shares of Compass Pathways by 67.7% during the first quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock valued at $26,000 after purchasing an additional 1,920 shares in the last quarter. Persistent Asset Partners Ltd bought a new stake in shares of Compass Pathways in the 4th quarter worth approximately $38,000. Parallel Advisors LLC boosted its position in shares of Compass Pathways by 8,450.6% in the 1st quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock worth $40,000 after purchasing an additional 7,183 shares in the last quarter. Advisory Services Network LLC purchased a new stake in shares of Compass Pathways in the 3rd quarter worth approximately $41,000. Finally, North Star Investment Management Corp. grew its stake in shares of Compass Pathways by 1,354.0% in the 1st quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock worth $42,000 after buying an additional 7,000 shares during the last quarter. 46.19% of the stock is owned by hedge funds and other institutional investors.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.